Effect of treatment with exenatide and pioglitazone or basal-bolus insulin on diabetic neuropathy: a substudy of the Qatar Study.

Ponirakis G, Abdul-Ghani MA, Jayyousi A, Almuhannadi H, Petropoulos IN, Khan A, Gad H, Migahid O, Megahed A, DeFronzo R, Mahfoud Z, Hassan M and 4 more

Show all authors

Al Hamad H, Ramadan M, Alam U, Malik RA

BMJ open diabetes research & care1 Jun 2020Cited by 59 (Europe PMC)

PMID32576561PMCIDPMC7312325DOI10.1136/bmjdrc-2020-001420PepBankPUB-32576561

Read at source PubMedAsk about this study

Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study7

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone7

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

01HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In poorly controlled T2D, exenatide plus pioglitazone reduced HbA1c from baseline.
In plain wordsIn T2D, exenatide plus pioglitazone reduced HbA1c from baseline.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseHbA1c
Study
n = 21
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Measurements
HbA1c decrease
35.2 mmol/mol
combination arm
HbA1c decrease
3.8%
combination arm
Source sentences
Summary
In the combination treatment arm (n=21), HbA1c decreased by 35.2 mmol/mol (3.8 %) (p<0.0001), body weight increased by 5.6 kg (p<0.0001), corneal nerve branch density increased (p<0.05), vibration perception worsened (p<0.05), and DN4 and sudomotor function showed no change.
2 context sentences(design, population, supporting numbers)
Summary · context
This is a substudy of the Qatar Study, an open-label, randomized controlled trial.
Summary · context
A combination of exenatide (2 mg/week) and pioglitazone (30 mg/day) or glargine with aspart insulin were randomly assigned to patients to achieve an HbA1c <53 mmol/mol (<7%).
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-3257656101
02HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In poorly controlled T2D, exenatide plus pioglitazone increased body weight from baseline.
In plain wordsIn T2D, exenatide plus pioglitazone increased weight from baseline.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseBody weight
Study
n = 21
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Measurements
Weight increase
5.6 kg
combination arm
Source sentences
Summary
In the combination treatment arm (n=21), HbA1c decreased by 35.2 mmol/mol (3.8 %) (p<0.0001), body weight increased by 5.6 kg (p<0.0001), corneal nerve branch density increased (p<0.05), vibration perception worsened (p<0.05), and DN4 and sudomotor function showed no change.
2 context sentences(design, population, supporting numbers)
Summary · context
This is a substudy of the Qatar Study, an open-label, randomized controlled trial.
Summary · context
A combination of exenatide (2 mg/week) and pioglitazone (30 mg/day) or glargine with aspart insulin were randomly assigned to patients to achieve an HbA1c <53 mmol/mol (<7%).
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-3257656102
03HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In T2D, exenatide plus pioglitazone increased corneal nerve branch density from baseline.
In plain wordsIn T2D, exenatide plus pioglitazone increased corneal nerve branch density from baseline.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseCorneal nerve branch density
Study
n = 21
Comparator
Baseline
Outcome group
Neuroprotection · Nervous system and cognition
Source sentences
Summary
In the combination treatment arm (n=21), HbA1c decreased by 35.2 mmol/mol (3.8 %) (p<0.0001), body weight increased by 5.6 kg (p<0.0001), corneal nerve branch density increased (p<0.05), vibration perception worsened (p<0.05), and DN4 and sudomotor function showed no change.
2 context sentences(design, population, supporting numbers)
Summary · context
This is a substudy of the Qatar Study, an open-label, randomized controlled trial.
Summary · context
A combination of exenatide (2 mg/week) and pioglitazone (30 mg/day) or glargine with aspart insulin were randomly assigned to patients to achieve an HbA1c <53 mmol/mol (<7%).
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-3257656103
04HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In T2D, vibration perception worsened from baseline with exenatide plus pioglitazone.
In plain wordsIn T2D, vibration perception worsened from baseline with exenatide plus pioglitazone.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseVibration perception
Study
n = 21
Comparator
Baseline
Outcome group
Neuroprotection · Nervous system and cognition
Source sentences
Summary
In the combination treatment arm (n=21), HbA1c decreased by 35.2 mmol/mol (3.8 %) (p<0.0001), body weight increased by 5.6 kg (p<0.0001), corneal nerve branch density increased (p<0.05), vibration perception worsened (p<0.05), and DN4 and sudomotor function showed no change.
2 context sentences(design, population, supporting numbers)
Summary · context
This is a substudy of the Qatar Study, an open-label, randomized controlled trial.
Summary · context
A combination of exenatide (2 mg/week) and pioglitazone (30 mg/day) or glargine with aspart insulin were randomly assigned to patients to achieve an HbA1c <53 mmol/mol (<7%).
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-3257656104
05HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In T2D, DN4 showed no change from baseline with exenatide plus pioglitazone.
In plain wordsIn T2D, DN4 showed no change from baseline with exenatide plus pioglitazone.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeDN4
Study
n = 21
Comparator
Baseline
Outcome group
Pain · Nervous system and cognition
Source sentences
Summary
In the combination treatment arm (n=21), HbA1c decreased by 35.2 mmol/mol (3.8 %) (p<0.0001), body weight increased by 5.6 kg (p<0.0001), corneal nerve branch density increased (p<0.05), vibration perception worsened (p<0.05), and DN4 and sudomotor function showed no change.
2 context sentences(design, population, supporting numbers)
Summary · context
This is a substudy of the Qatar Study, an open-label, randomized controlled trial.
Summary · context
A combination of exenatide (2 mg/week) and pioglitazone (30 mg/day) or glargine with aspart insulin were randomly assigned to patients to achieve an HbA1c <53 mmol/mol (<7%).
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-3257656105
06HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome
In T2D, sudomotor function showed no change from baseline with exenatide plus pioglitazone.
In plain wordsIn T2D, sweating function showed no change from baseline with exenatide plus pioglitazone.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeSudomotor function
Study
n = 21
Comparator
Baseline
Outcome group
Neuroprotection · Nervous system and cognition
Source sentences
Summary
In the combination treatment arm (n=21), HbA1c decreased by 35.2 mmol/mol (3.8 %) (p<0.0001), body weight increased by 5.6 kg (p<0.0001), corneal nerve branch density increased (p<0.05), vibration perception worsened (p<0.05), and DN4 and sudomotor function showed no change.
2 context sentences(design, population, supporting numbers)
Summary · context
This is a substudy of the Qatar Study, an open-label, randomized controlled trial.
Summary · context
A combination of exenatide (2 mg/week) and pioglitazone (30 mg/day) or glargine with aspart insulin were randomly assigned to patients to achieve an HbA1c <53 mmol/mol (<7%).
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-3257656106
07HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialOther
In the T2D substudy, CCM changes showed no association with changes in HbA1c, weight or lipids.
In plain wordsIn the T2D substudy, corneal nerve changes showed no association with changes in HbA1c, weight or lipids.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeCCM change associations
Study
n: not reported in source
Outcome group
Neuroprotection · Nervous system and cognition
Source sentences
Summary
There was no association between the change in CCM measures with change in HbA1c, weight or lipids.
2 context sentences(design, population, supporting numbers)
Summary · context
This is a substudy of the Qatar Study, an open-label, randomized controlled trial.
Summary · context
A combination of exenatide (2 mg/week) and pioglitazone (30 mg/day) or glargine with aspart insulin were randomly assigned to patients to achieve an HbA1c <53 mmol/mol (<7%).
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-3257656107

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.